Related Experiment Video
Updated: Aug 17, 2026

Determination of Biofilm Initiation on Virus-infected Cells by Bacteria and Fungi
Published on: July 6, 2016
Developments in STD/HIV interactions: the intertwining epidemics of HIV and HSV-2
Steven J Reynolds1, Thomas C Quinn
1Division of Infectious Diseases, Johns Hopkins University School of Medicine, Ross 1159, 720 Rutland Avenue, Baltimore, MD 21205, USA. sreynol6@jhmi.edu
Abstract:
Antiviral agents aimed at treating HSV-2 chronically infected individuals have proven to be effective in the prevention of symptomatic genital herpes and the reduction of viral shedding. These agents play a key role in current HIV prevention trials that will assess the role of suppression of HSV-2 infection on the risk for HIV acquisition and transmission. An added clinical benefit of treating HSV-2/HIV-coinfected individuals is the potential survival benefit, as suggested by earlier studies and by the recent findings that HSV-2/HIV dually infected individuals have higher viral loads. The results of the current HSV-2 suppression trials may provide additional tools to fight the global spread of HIV infection. Treatment of HSV-2/HIV dually infected individuals may prove to be a low-cost intervention to improve clinical outcomes and delay the need for antiretroviral therapy.
Related Concept Videos
Genital Herpes
Sexually Transmitted Infections
Herpes
Retrovirus Life Cycles
Viral Recombination
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
